Mestinon

Pyridostigmine bromide, the active ingredient in Mestinon, is an anticholinesterase presented as an oral tablet for oral use. It is used to improve muscle strength in patients with myasthenia gravis and to reverse the effects of non‑depolarizing neuromuscular blocking agents after surgery.

GNH USA supplies Mestinon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide. The company adheres to stringent quality standards, offers batch‑to‑batch consistency, and provides reliable logistics for global distribution, ensuring timely delivery to authorized healthcare providers.

Mestinon, an anticholinesterase, acts on the neuromuscular junction to improve transmission in conditions characterized by muscle weakness.

Myasthenia gravis: enhances skeletal muscle strength in patients with this autoimmune disorder. Reversal of non‑depolarizing neuromuscular blockade: restores normal neuromuscular function after surgical anesthesia. Myasthenic syndrome secondary to certain medications: alleviates muscle weakness caused by drug‑induced cholinergic blockade.

Mestinon may cause a range of adverse reactions, most of which are related to excess cholinergic activity.

Common Side Effects: - Nausea - Diarrhea - Abdominal cramps - Increased salivation

Serious or Rare Side Effects: - Bradycardia - Severe bronchospasm - Cholinergic crisis (muscle weakness, respiratory failure)

Before prescribing Mestinon, clinicians should consider several safety measures.

Dose adjustment: modify dosage in patients with renal impairment to avoid accumulation. Monitor for cholinergic excess: watch for signs such as muscle twitching, sweating, or gastrointestinal upset. Avoid use in severe asthma or COPD: risk of bronchospasm may be heightened. Pregnancy caution: safety category is unknown; use only if benefits outweigh risks. Do not discontinue abruptly: tapering may be required to prevent rebound weakness. Store at ambient temperature: keep in the original pack, protect from moisture.

Mestinon can interact with other medications, requiring careful management.

Major Interactions (Avoid): - Anticholinergic agents (e.g., atropine) – may diminish therapeutic effect. - Beta‑blockers – can exacerbate bradycardia. - Magnesium sulfate – may potentiate neuromuscular blockade.

Moderate Interactions (Monitor Closely): - Aminoglycoside antibiotics – may increase neuromuscular blockade. - Inhaled anesthetics – can enhance cholinergic side effects. - Diuretics – may alter potassium balance, affecting drug activity.